-+ 0.00%
-+ 0.00%
-+ 0.00%

After an advanced trial of Ultragenyx Pharma's advanced bone disease drug failed, the stock price plummeted 43%.

智通財經·12/29/2025 14:41:06
語音播報
After an advanced trial of Ultragenyx Pharma's advanced bone disease drug failed, the stock price plummeted 43%.